- Active not recruitingPHASE1
Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)
This study tests a new medicine called zongertinib for advanced cancers with changes in the HER2 gene. It aims to find the right dose and see if it can shrink tumours, especially in non-small cell lung cancer.
For: Neoplasm Metastasis · Non-Small Cell Lung CancerUnited States · Australia · Austria - Active not recruitingPHASE3
Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
This study looks at a new drug, zongertinib, for advanced lung cancer with a specific genetic change (HER2 mutation). It compares zongertinib to standard treatment to see if it can better slow down cancer growth and improve how long people live without their cancer getting worse.
For: Lung Cancer, Non-squamous, Non-small CellUnited States · Argentina · Australia - RecruitingPHASE2
Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations
This study is looking into a new medicine called zongertinib for people with advanced cancers. It focuses on cancers where HER2, a protein, has changed. The goal is to see if zongertinib can help by blocking these changes in HER2.
For: Solid TumoursUnited States · Australia · Belgium - RecruitingPHASE1, PHASE2
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
This study looks at a new drug, zongertinib, for different HER2+ cancers that have spread. Researchers want to find the best dose, alone and with other treatments, to see if it can shrink tumours.
For: Metastatic Breast Cancer · Metastatic Gastric Adenocarcinoma · Gastroesophageal Junction AdenocarcinomaUnited States · Belgium · China - RecruitingPHASE3
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
This study is for adults with a certain type of lung cancer (Stage II-IIIB non-small cell lung cancer) that has a specific genetic change (HER2 mutation) and has been fully removed by surgery. It compares a new daily tablet called zongertinib with standard treatments to see if it can stop the cancer from coming back.
For: Non-small Cell Lung CancerUnited States · Argentina · Australia